Sinclair Dunlop - Sep 8, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Sinclair Dunlop
Stock symbol
APLS
Transactions as of
Sep 8, 2022
Transactions value $
-$975,000
Form type
4
Date filed
9/8/2022, 04:38 PM
Previous filing
Aug 26, 2022
Next filing
Nov 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale -$975K -15K -5.87% $65.00 241K Sep 8, 2022 Indirect Owner (Epidarex) F1
holding APLS Common Stock 130K Sep 8, 2022 Direct
holding APLS Common Stock 31.9K Sep 8, 2022 Indirect Owner (Masa) F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
F2 The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.